← Back to Search

Glutamate Receptor Antagonist

Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm

Phase 2
Waitlist Available
Research Sponsored by Addex Pharma S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 2

Summary

This trial is testing a medication called dipraglurant to help people with blepharospasm, a condition causing involuntary eye muscle contractions. The study will check if the medication is safe and if it can reduce the severity and frequency of these muscle spasms. Dipraglurant works by blocking certain brain signals that cause the spasms.

Eligible Conditions
  • Blepharospasm
  • Limb Dystonia
  • Eyelid Twitching
  • Dystonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 2
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 2 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Computerized Motor Objective Rater (CMOR) analysis of blinking activity
Safety and tolerability of dipraglurant as measured by incidence of adverse events
Skintronics wearable analysis of blinking activity
Secondary study objectives
Blepharospasm Disability Index (BSDI)
Blepharospasm Phenotyping Tool (BPT)
Blepharospasm Severity Rating Scale (BSRS)
+5 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Dipraglurant 50 mgExperimental Treatment1 Intervention
Group II: Dipraglurant 100 mgExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Addex Pharma S.A.Lead Sponsor
7 Previous Clinical Trials
1,143 Total Patients Enrolled
~4 spots leftby Dec 2025